An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review

Pharmacol Rep. 2021 Oct;73(5):1265-1272. doi: 10.1007/s43440-021-00257-9. Epub 2021 Apr 11.

Abstract

Human immunodeficiency virus-1 (HIV-1) infection remains to be one of the major threats throughout the world. Many researchers are working in this area to find a cure for HIV-1. The group of the FDA approved drugs which are currently used against HIV-1 in the clinical practice include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (InIs), and protease inhibitors (PIs). Fixed dose combinations (FDCs) of these drugs are available and are used as per the anti-retroviral therapy (ART) guidelines. Despite these, unfortunately, there is no cure for HIV1 infection to date. The present review is focused upon describing the importance of a post-transcriptional regulatory protein "Rev", responsible for latent HIV-1 infection as a possible, and promising therapeutic target against HIV-1.

Keywords: ABX464; HIV-1 infections; Latent HIV-1 infection; Rev protein.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Drug Delivery Systems*
  • Gene Expression Regulation, Viral / drug effects
  • HIV Infections / drug therapy*
  • HIV-1*
  • Humans
  • rev Gene Products, Human Immunodeficiency Virus / genetics
  • rev Gene Products, Human Immunodeficiency Virus / metabolism*

Substances

  • Anti-HIV Agents
  • rev Gene Products, Human Immunodeficiency Virus
  • rev protein, Human Immunodeficiency Virus-1